← Back to Search

PET Imaging for Melanoma

N/A
Waitlist Available
Led By Hilda Stambuk, MD
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Newly diagnosed patients with previous excisional biopsy
18 years of age or older
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

This trial will study whether the investigational particle can help find cancer in people who have already had a CAT scan or MRI that showed possible cancer.

Who is the study for?
This trial is for adults with a confirmed diagnosis of melanoma or malignant brain tumor at MSKCC, who may have had prior treatments like surgery, chemo, or radiation. They must be able to use birth control and not have other recent cancers (except the one being studied), uncontrolled illnesses, severe heart disease, thyroid dysfunction, allergies to iodine contrast material, weigh over 400 lbs., or suffer from claustrophobia.Check my eligibility
What is being tested?
The study tests a new PET scan dye carried by nanoparticles designed to target cancer areas more precisely than current imaging methods. This microdosing study aims to see how well the dye works in humans after being proven safe in mice. It's important to note that this particle won't treat cancer; it's purely for improving detection.See study design
What are the potential side effects?
Since this is an imaging study using a tracer particle and not a drug treatment trial per se, specific side effects are not detailed but could include reactions related to the injection such as pain or swelling at the injection site.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I was recently diagnosed and had a lump removed for testing.
Select...
I am 18 years old or older.
Select...
I've had treatment or surgery in my head/neck and need flap reconstruction.
Select...
I have a new or returning melanoma or brain tumor with visible signs of the tumor.
Select...
I have been cancer-free from any cancer other than melanoma or brain tumor for over 5 years.
Select...
My melanoma or brain tumor diagnosis was confirmed through tissue analysis at MSKCC.
Select...
My heart is healthy based on my last check-up.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Conduct pilot single-dose studies of 124I-cRGDY-PEG-dots†
Secondary outcome measures
Assay particle tracer tissue distributions in tumor tissue specimens
Estimate the radiation dosimetry of i.v.-injected 124I-cRGDY-PEG-dots.

Trial Design

1Treatment groups
Experimental Treatment
Group I: newly diagnosed or recurrent head/neck melanomaExperimental Treatment1 Intervention
This is a two-year microdosing study that will enroll 5 metastatic melanoma patients and 18 malignant brain tumor patients (surgical (n=13) and non-surgical candidates (n=5)). We have already accrued 5 melanoma patients and expect to accrue brain tumor patients within a 1 year period.

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,928 Previous Clinical Trials
591,798 Total Patients Enrolled
76 Trials studying Melanoma
15,968 Patients Enrolled for Melanoma
Hilda Stambuk, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
1 Previous Clinical Trials
67 Total Patients Enrolled
1 Trials studying Melanoma
67 Patients Enrolled for Melanoma
Michelle Bradbury, MD,PhDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center

Media Library

PET scan with 124I-cRGDY-PEG-dots Clinical Trial Eligibility Overview. Trial Name: NCT01266096 — N/A
Melanoma Research Study Groups: newly diagnosed or recurrent head/neck melanoma
Melanoma Clinical Trial 2023: PET scan with 124I-cRGDY-PEG-dots Highlights & Side Effects. Trial Name: NCT01266096 — N/A
PET scan with 124I-cRGDY-PEG-dots 2023 Treatment Timeline for Medical Study. Trial Name: NCT01266096 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is recruitment still underway for this medical experiment?

"According to information posted at clinicaltrials.gov, this study is no longer seeking new candidates. Initially published on January first 2011 and most recently updated September 13th 2022, the trial has reached its recruitment goal of 1126 participants but other studies are still recruiting patients."

Answered by AI
~0 spots leftby Dec 2024